tbuckley/cabot-search huggingface dataset:
SO-21 Optimal maintenance treatment strategy following an anti-EGFR-based first-line induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of clinical trials
Authors: A. Raimondi, F. Morano, T. Trarbach, M. Karthaus, S. Lonardi, S. Fruehauf, C. Cremolini, U. Graeven, A. Bittoni, L. Mueller, A. Sartore Bianchi, E. Aranda, V. Boige, S. Stintzing, M. Di Bartolomeo, A. Koenig, F. Pietrantonio, D. Modest
Journal: Annals of Oncology (2022)
P-192 Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumors sensitive to imatinib: A retrospective analysis of 2 Russian cancer centers
Authors: D. Filonenko, L. Zhukova, P. Arkhiri, M. Nikulin, I. Sagaidak, V. Yugay, A. Meshcheryakov
Journal: Annals of Oncology (2022)
P-19 Subgroup analysis of the number of prior lines of systemic therapy and clinical outcomes associated with tislelizumab in patients with previously treated advanced hepatocellular carcinoma (HCC)
Authors: P. Merle, J. Edeline, W. Fang, E. Assenat, H. Pan, L. Rimassa, Z. Li, J. Blanc, C. Yen, P. Ross, S. Hu, T. Zhang, A. Tran, G. Shao, M. Bouattour, Y. Chen, J. Wu, B. Li, S. Chica-Duque, Z. Ren
Journal: Annals of Oncology (2022)
P-229 Comparison of clinicopathological and survival features of right and left colon cancers: Experience of the medical oncology department of Fez
Authors: S. El Anssari, Z. Benbrahim, Y. Elhaitmy, I. Elbadisy, F. Abbass, L. Amaadour, K. Oualla, S. Arifi, K. Elghazi, M. Nawfel
Journal: Annals of Oncology (2022)
P-244 Feasibility, safety, and biodistribution of 18F-BMS-986229 PET in patients with esophagogastric (EG) cancer
Authors: S. Cytryn, M. Lumish, V. Paroder, S. Philemond, J. Lewis, S. Lyashchenko, Y. Janjigian, N. Pandit-Taskar
Journal: Annals of Oncology (2022)
P-15 Histology classification highlights the difference in the effectiveness of S-1 over capecitabine when combined with cisplatin in patients with HER2-negative unresectable advanced or recurrent gastric cancer with measurable disease
Authors: H. Kawakami, K. Nishikawa, T. Shimokawa, K. Fujitani, S. Tamura, S. Endo, M. Kobayashi, J. Kawada, Y. Kurokawa, A. Tsuburaya, T. Yoshikawa, J. Sakamoto, T. Satoh
Journal: Annals of Oncology (2022)
P-32 Different regimens of the 1st line chemotherapy in patients (pts) with metastatic anal cancer: Results of the multicenter observational study
Authors: M. Fedyanin, E. Ignatova, N. Besova, S. Gordeyev, M. Chernih, A. Tryakin, E. Rybakov, V. Ivanov
Journal: Annals of Oncology (2022)
P-66 PET/CT radiomic features to predict clinical outcomes in locally advanced pancreatic cancer
Authors: M. Fiore, E. Cordelli, P. Trecca, G. Petrianni, G. D'Ercole, E. Ippolito, R. Coppola, M. Calcagni, P. Soda, S. Ramella
Journal: Annals of Oncology (2022)
P-268 Molecular signature and MMR status of early- and late-onset colorectal cancer among Arabs
Authors: A. AlZaabi, H. ALAdawi, M. ALShaibi, A. AlShihi, F. AlFarsi, O. AlAlyani, A. AlMirza, M. AlAsmi, T. AlBarhi, S. abd Elmoety
Journal: Annals of Oncology (2022)
P-91 Quality of life (QoL)-based end-points for patients with advanced pancreatic ductal adenocarcinoma (aPDAC): Results from the PanDA prospective observational study
Authors: A. Lamarca, L. Carnie, D. Shah, K. Vaughan, Z. Kapacee, L. McCallum, M. Abraham, A. Backen, L. Gillespie, M. McNamara, R. Hubner, J. Valle
Journal: Annals of Oncology (2022)
P-175 Local inflammatory biomarkers and their association with systemic inflammation as well as overall survival in primary metastatic gastroesophageal cancer patients
Authors: H. Puhr, T. Hatziioannou, A. Beer, R. Kain, G. Jomrich, M. Paireder, S. Schoppmann, A. Berghoff, M. Preusser, A. Ilhan-Mutlu
Journal: Annals of Oncology (2022)
P-205 Concordance between RAS and BRAF mutational status determination in ctDNA and tissue in patients with mCRC
Authors: E. Terán Brage, R. Vidal Tocino, A. Rodrígues Francoso, B. Rivas López, Á. López Gutiérrez, L. Figuero Pérez, J. Claros Ampuero, B. Cigarral García, E. Fonseca Sánchez, J. Cruz Hernández
Journal: Annals of Oncology (2022)
P-246 Real-world outcomes in metastatic colorectal patients receiving regorafenib treatment in China
Authors: W. Qu, Z. Jiang, Z. Liu, L. Zhu, X. Chen, B. Liu, Y. Zhao, S. Li, H. Yan, X. Qu, A. Zang, Y. Sun, A. Zhou
Journal: Annals of Oncology (2022)
P-82 Evaluation of prognostic tools in locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy
Authors: P. Gómez Mugarza, E. Polo, B. López Roldán, S. Barriendos Sanz, M. Monreal Cepero, S. Campos Ramírez, F. Mocha Campillo, P. Trincado Cobos, A. Comin, J. Ponce, V. Navarro Aznar, I. Gurruchaga Sotés, A. Nuño Alves, M. Felices Lobera, V. Alonso Orduña
Journal: Annals of Oncology (2022)
P-156 MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress
Authors: J. Tabernero, J. Strickler, Y. Nakamura, K. Shitara, Y. Janjigian, A. Barzi, T. Bekaii-Saab, H. Lenz, T. Yoshino, S. Siena, J. Garrido-Mayor, M. Ubowski, D. Xie, J. Marshall
Journal: Annals of Oncology (2022)
P-50 RETRO-TAS, a retrospective observational study of rifluridine/tipiracil in chemorefractory metastatic colorectal cancer
Authors: A. Koumarianou, A. Ntavatzikos, G. Vourli, D. Symeonidis, C. Vallilas, S. Xynogalos, I. Boukovinas, G. Papaxoinis, S. Demiri, K. Kampoli, G. Oikonomopoulos, M. Giannakakou, E. Samantas, E. Res, N. Androulakis, M. Karamouzis, J. Souglakos
Journal: Annals of Oncology (2022)
P-18 Prognostic association between (so over-expression of vascular) of vascular endothelial growth factor receptor and micro-vascular invasion in patients with hepatocellular carcinoma
Authors: N. Enkhbaatar, O. Gankhuu, O. Munkhbold, B. Bayarkhuu, O. Batdelger, M. Davaa, V. Seesregdorj, T. Purevsukh, T. Dash
Journal: Annals of Oncology (2022)
P-158 Comprehensive recurrence risk assessment after colectomy, for stage II and III colorectal cancer patients, using genetic profiling, microbiome, and circulating tumor markers
Authors: I. Messaritakis, M. Sfakianaki, A. Koulouris, M. Chondrozoumaki, M. Karagianni, E. Xynos, M. Christodoulakis, D. Mavroudis, J. Souglakos
Journal: Annals of Oncology (2022)
P-40 Clinico-pathological characteristics and outcomes of patients with early-onset colorectal cancer
Authors: D. Viñal, S. Martinez-Recio, I. Ruiz, D. Jimenez-Bou, J. Peña, G. Martin-Montalvo, A. Rueda-Lara, M. Alameda, I. Prieto, A. Muñoz, J. Rodriguez-Cobos, P. Bustamante, M. Larriba, I. Ghanem, A. Fernandez-Barral, J. Feliu, A. Barbachano, J. Gonzalez-Sancho, A. Burgos, L. G-Pastrián, N. Rodríguez-Salas
Journal: Annals of Oncology (2022)
Evidence of co-infections during Delta and Omicron SARS-CoV-2 variants co-circulation through prospective screening and sequencing
Authors: Patricia Combes, Maxime Bisseux, Antonin Bal, Pierre Marin, Justine Latour, Christine Archimbaud, Amélie Brebion, Hélène Chabrolles, Christel Regagnon, Jérémy Lafolie, Gregory Destras, Bruno Simon, Jacques Izopet, None Laurence Josset, Cécile Henquell, Audrey Mirand
Journal: Clinical Microbiology and Infection (2022)

To describe Delta/Omicron SARS-CoV-2 variants co-infection detection and confirmation during the fifth wave of COVID-19 pandemics in France in 7 immunocompetent and epidemiologically unrelated patients.
P-22 Phase III study (daNIS-2) of the anti–TGF-β monoclonal antibody NIS793 with nab-paclitaxel/gemcitabine vs nab-paclitaxel/gemcitabine alone in patients with first-line metastatic pancreatic ductal adenocarcinoma
Authors: E. O'Reilly, T. Golan, M. Ikeda, M. Milella, J. Taieb, Z. Wainberg, L. Wang, N. Gyambibi, E. López, K. Xu, T. Macarulla
Journal: Annals of Oncology (2022)
P-109 Care delivery impact of the COVID-19 pandemic on anal cancer care
Authors: E. Saldanha, M. Powis, F. Cavalher, S. Hack, M. Simoes, M. Costa, A. Baiad, Z. Mohmand, K. Chen, P. Nakhla, O. Espin-Garcia, L. Huaqi, R. Riechelmann, M. Krzyzanowska
Journal: Annals of Oncology (2022)
Recovery of <i>Bacteroides thetaiotaomicron</i> ameliorates hepatic steatosis in experimental alcohol-related liver disease
Authors: Moris Sangineto, Christoph Grander, Felix Grabherr, Lisa Mayr, Barbara Enrich, Julian Schwärzler, Marcello Dallio, Vidyasagar Naik Bukke, Archana Moola, Antonio Moschetta, Timon E. Adolph, Carlo Sabbà, Gaetano Serviddio, Herbert Tilg
Journal: Gut Microbes (2022)

Alcohol-related liver disease (ALD) is a major cause of liver disease and represents a global burden, as treatment options are scarce. Whereas 90% of ethanol abusers develop alcoholic fatty liver disease (AFLD), only a minority evolves to steatohepatitis and cirrhosis. Alcohol increases lipogenesis and suppresses lipid-oxidation implying steatosis, although the key role of intestinal barrier integrity and microbiota in ALD has recently emerged. Bacteroides thetaiotaomicron (Bt) is a prominent member of human and murine intestinal microbiota, and plays important functions in metabolism, gut immunity, and mucosal barrier. We aimed to investigate the role of Bt in the genesis of ethanol-induced liver steatosis. Bt DNA was measured in feces of wild-type mice receiving a Lieber-DeCarli diet supplemented with an increase in alcohol concentration. In a second step, ethanol-fed mice were orally treated with living Bt, followed by analysis of intestinal homeostasis and histological and biochemical alterations in the liver. Alcohol feeding reduced Bt abundance, which was preserved by Bt oral supplementation. Bt-treated mice displayed lower hepatic steatosis and triglyceride content. Bt restored mucosal barrier and reduced LPS translocation by enhancing mucus thickness and production of Mucin2. Furthermore, Bt up-regulated Glucagon-like peptide-1 (GLP-1) expression and restored ethanol-induced Fibroblast growth factor 15 (FGF15) down-regulation. Lipid metabolism was consequently affected as Bt administration reduced fatty acid synthesis (FA) and improved FA oxidation and lipid exportation. Moreover, treatment with Bt preserved the mitochondrial fitness and redox state in alcohol-fed mice. In conclusion, recovery of ethanol-induced Bt depletion by oral supplementation was associated with restored intestinal homeostasis and ameliorated experimental ALD. Bt could serve as a novel probiotic to treat ALD in the future.
P-33 Prognostic impact of single organ pulmonary metastasis in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy
Authors: H. Osumi, O. Akira, K. Shimozaki, I. Nakayama, T. Wakatsuki, D. Takahari, K. Chin, K. Yamaguchi, E. Shinozaki
Journal: Annals of Oncology (2022)
P-14 Safety and short-term efficacy of preoperative FOLFOX therapy for patients with resectable esophageal squamous cell carcinoma who are not candidates for cisplatin
Authors: T. Kadono, S. Yamamoto, A. Ohara, M. Itouyama, K. Yokoyama, Y. Honma, K. Ishiyama, J. Oguma, H. Daiko, K. Kato
Journal: Annals of Oncology (2022)
P-128 Pathologic complete response to neoadjuvant chemoradiation as a predictor of survival in Latin American patients with rectal cancer
Authors: G. Calderillo-Ruiz, C. Diaz, J. Villanueva Domínguez, H. Lopez Basave, B. Carbajal-López, E. Ruiz-Garcia, M. Herrera, W. Muñoz, V. Itzel, C. Perez Plascencia
Journal: Annals of Oncology (2022)
A promising preclinical model for <i>TERT</i> promoter mutation in glioblastoma
Authors: Jason T Huse
Journal: Neuro-Oncology (2022)

Journal Article A promising preclinical model for TERT promoter mutation in glioblastoma Get access Jason T Huse Jason T Huse Department of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA Corresponding Author: Jason T. Huse, MD, PhD, 2130 W Holcombe Blvd, LSP9.4009, Unit 2951, Houston, TX 77030, USA (JHuse@mdanderson.org). Search for other works by this author on: Oxford Academic PubMed Google Scholar Neuro-Oncology, Volume 24, Issue 12, December 2022, Pages 2076–2077, https://doi.org/10.1093/neuonc/noac167 Published: 03 July 2022 Article history Published: 03 July 2022 Corrected and typeset: 25 July 2022
P-104 Overexpression of mir-224-3p in extrahepatic cholangiocarcinoma associated with increased dose of I131 radiotherapy: An in vitro study
Authors: M. Calastri, R. Ferreira, P. Jordão, S. Júnior, L. Spinola, G. Tenani, G. Vieira, L. Napoli, E. Zanovelo, D. de Souza, M. Botelho, A. Abrantes, A. de Brito, J. Tralhão, R. da Silva, R. da Silva, L. da Costa, I. Boin, D. Souza
Journal: Annals of Oncology (2022)
P-58 Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol
Authors: F. Huemer, S. Hecht, B. Scharinger, V. Schlintl, G. Rinnerthaler, K. Schlick, R. Heregger, T. Melchardt, A. Wimmer, I. Mühlbacher, O. Koch, D. Neureiter, E. Klieser, S. Seyedinia, M. Beheshti, R. Greil, L. Weiss
Journal: Annals of Oncology (2022)
P-83 The impact of the multidisciplinary team (MDT) in the management of colorectal cancer (CRC)
Authors: F. Schietroma, M. Bensi, B. Barbaro, M. Calegari, C. Cina, R. Menghi, L. Lorenzon, C. Pozzo, M. Basso, A. Anghelone, G. Valente, F. Lococo, F. Ardito, F. Cellini, G. Caira, G. Trovato, D. D'Ugo, F. Giuliante, G. Tortora, L. Salvatore
Journal: Annals of Oncology (2022)
P-208 Fluoropyrimidine- and irinotecan-induced toxicity profile associated with mutations in DPYD and UGT1A1 genes
Authors: E. Terán Brage, B. Cigarral García, D. Heredero Jung, B. García Berrocal, M. Navarro Martín, M. Navalón Jiménez, E. Fonseca Sánchez, R. Vidal Tocino
Journal: Annals of Oncology (2022)
P-237 Percentage of residual fibrosis versus Rubbia-Brandt classification as predictors of overall survival in metastatic colorectal cancer. Which is better?
Authors: X. Hernández-Yagüe, R. Ortiz-Duran, S. Lopez-Ben, C. Meléndez-Muñoz, M. Buxó, L. Llavata, E. Castro-Gutiérrez, L. Falgueras-Verdaguer, B. Fuertes-Negro, J. Brunet-Vidal, J. Figueras-Felip
Journal: Annals of Oncology (2022)
P-10 Standardization of a neoadjuvant therapy (NAT) pathway for pancreatic cancer across a geographically large and diverse healthcare system improves patient care and successful completion of NAT
Authors: R. Parakrama, B. Sidiqi, L. Demyan, S. Pasha, D. Pinto, T. Zavadsky, X. Zou, S. Patruni, A. Kapusta, O. Standring, M. Weiss, J. Herman, D. King
Journal: Annals of Oncology (2022)
P-271 Frequency of RAS variants in Bulgarian patients with metastatic colorectal cancer
Authors: N. Nazifova-Tasinova, G. Mihaylova, G. Stoyanov, O. Tasinov, V. Draganova, A. Zlatarov, N. Kolev, N. Tsonev, M. Radanova
Journal: Annals of Oncology (2022)
PD-8 Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study
Authors: T. Okusaka, M. Kitano, M. Chen, J. Chen, V. Ostwal, M. McNamara, V. Breder, M. Petrova, G. Buchschacher, N. Rokutanda, J. Xiong, G. Cohen, D. Oh
Journal: Annals of Oncology (2022)
P-4 Efficacy and safety of sintilimab combined nab-paclitaxel and gemcitabine as first-line treatment for metastatic pancreatic ductal adenocarcinoma (PDAC): A retrospective analysis
Authors: J. Wang, Y. He, H. Lv, B. Chen, C. Nie, W. Xu, J. Zhao, B. Zhang, X. Cheng, None Q. li, S. Tu, X. Chen
Journal: Annals of Oncology (2022)
P-127 Multi-institutional analysis of real-world activity and safety of trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer
Authors: G. Arrichiello, E. Martinelli, T. Troiani, P. Incoronato, V. Nacca, F. Paragliola, R. Napolitano, G. Suarato, A. Nicastro, A. Perrone
Journal: Annals of Oncology (2022)
P-206 Association between primary tumor site of colorectal cancer and RAS/BRAF mutational status with venous thromboembolism: A retrospective-prospective cohort study from 3 Croatian oncology centers
Authors: J. Jović Zlatović, M. Bevanda, M. Skelin, V. Telesmanić Dobrić, Z. Curić, I. Marijanović, F. Grubisić-Čabo, I. Krečak, S. Tomić, K. Kralik, T. Omrčen
Journal: Annals of Oncology (2022)
P-226 Outcomes using induction chemotherapy followed by long-course chemoradiotherapy as total neoadjuvant therapy for locally advanced rectal cancer
Authors: E. Gatfield, J. Hughes, M. Kumaran, G. Doherty, M. Daly, M. Stancliffe, C. Jephcott, C. Wilson, S. Smith, R. Jadon
Journal: Annals of Oncology (2022)
P-44 Impact of regorafenib dose optimization on clinical outcomes compared to best supportive care and TAS-102 in the treatment of relapsed/refractory metastatic colorectal cancer
Authors: T. Bekaii-Saab, H. Burnett, I. Proskorovsky, S. Yoon, Y. Wang, H. Ostojic, L. Gaianu, Y. Su
Journal: Annals of Oncology (2022)
P-35 An observational study of health-related quality of life (HRQoL) with electronic patient-reported outcome (ePRO) monitoring during nivolumab therapy for advanced gastric cancer as the 3rd or later line treatment: NIVO-G QoL study
Authors: H. Kawakami, S. Oyamada, Y. Horie, S. Fumita, N. Izawa, T. Miyaji, T. Kawaguchi, T. Yamaguchi, T. Nakajima
Journal: Annals of Oncology (2022)
P-94 Circulating-tumour DNA (ctDNA) detection using an ultra-sensitive next generation sequencing (NGS)-based assay in patients with resected colorectal cancer (CRC) in the phase III ASCOLT trial
Authors: D. Day, A. Starus, O. Sieber, D. Prasse, A. Lamik, J. Fredebohm, J. Simes, F. Day, M. Jeffery, R. Zielinski, M. Singh, G. Chong, S. Li, D. Mouradov, J. Chia, R. Ali, H. Toh, F. Jones, E. Segelov
Journal: Annals of Oncology (2022)
P-141 Lenvatinib activates potential anti-tumor immunity by increasing infiltration of immune cells and interferon response in tumor microenvironment of advanced hepatocellular carcinoma
Authors: M. Yamauchi, A. Ono, K. Amioka, Y. Fujii, S. Uchikawa, H. Fujino, T. Nakahara, E. Murakami, W. Okamoto, T. Kawaoka, D. Miki, M. Tsuge, M. Imamura, H. Nelson, Y. Kato, M. Kimura, N. Suzuki, H. Aikata, K. Chayama
Journal: Annals of Oncology (2022)
P-117 Circulating tumor DNA in metastatic colorectal cancer: Real-time monitoring of disease evolution and treatment response
Authors: G. Marisi, M. Urbini, G. Bartolini, I. Azzali, C. Molinari, M. Canale, F. Sullo, G. Tedaldi, F. Rebuzzi, E. Chiadini, L. Capelli, D. Angeli, G. Frassineti, P. Ulivi, A. Passardi
Journal: Annals of Oncology (2022)
P-173 Understanding the treatment algorithm of patients with advanced G2 gastroenteropancreatic neuroendocrine neoplasms: A single-institution retrospective analysis
Authors: M. Peri, L. Incorvaia, V. Spinnato, L. Corsini, R. Scalia, A. Dimino, L. Algeri, R. Schiacchitano, L. Magrin, A. Galvano, V. Gristina, S. Cusenza, V. Bazan, G. Badalamenti, A. Russo
Journal: Annals of Oncology (2022)
P-54 Phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: Cohort of subjects with checkpoint inhibitor-naïve advanced MSS-colorectal cancer
Authors: R. Kim, H. Mamdani, M. Barve, M. Johnson, I. Sahin, S. Kopetz, S. Yang, B. Lee, T. Adebanjo, R. Georgevitch, S. Ferrando-Martinez, M. Chaney, J. Fan, A. Naing
Journal: Annals of Oncology (2022)
P-68 Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): An academic, multicenter, single-arm, two-stage, phase 2 study
Authors: C. Cardone, M. Piccirillo, G. Rosati, A. De Stefano, C. Romano, A. Nappi, N. Zanaletti, F. Foschini, A. Cassata, R. Casaretti, L. Silvestro, F. Tatangelo, S. Lastoria, M. Raddi, D. Bilancia, A. Febbraro, E. Martinelli, F. Ciardiello, P. Delrio, F. Perrone, A. Budillon, A. Avallone
Journal: Annals of Oncology (2022)
P-77 A phase II study of multiple kinase inhibitor, TT-00420, in advanced, refractory cholangiocarcinoma
Authors: M. Javle, A. Mahipal, D. Li, C. Fountzilas, P. Peng, W. Levin, B. Ngo, A. Chen, H. Wang, C. Sun, Q. Ru, F. Wu
Journal: Annals of Oncology (2022)
P-123 A phase Ia/Ib, open-label, dose-escalation study of the TRAILR2 agonist BI 905711 in combination with chemotherapy in patients with advanced gastrointestinal cancers
Authors: S. Kopetz, E. Van Cutsem, Y. Kuboki, B. Johnson, T. Katakabe, J. Geng, S. Archuadze, L. Shen
Journal: Annals of Oncology (2022)
P-137 Efficacy and safety of atezolizumab plus bevacizumab in unresectable or advanced hepatocellular carcinoma: Real life data from 5 Swiss centers
Authors: B. Norero, A. Siebenhuener, T. Kössler, N. Usdin, D. Semela, R. Stillhard, P. Meyer-Herborn, I. Bergamin, R. Fritsch, A. Kremer, S. Blümel, S. Hussung, B. Schwacha-Eipper
Journal: Annals of Oncology (2022)
P-106 Evaluating sex as a predictive marker for response to bevacizuamb in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database
Authors: O. Margalit, W. Harmsen, E. Shacham-Shmueli, M. Voss, B. Boursi, R. Cohen, C. Olswold, L. Saltz, H. Hurwitz, R. Adams, B. Chibaudel, A. Grothey, T. Yoshino, J. Zalcberg, A. de Gramont, Q. Shi, H. Lenz
Journal: Annals of Oncology (2022)
P-25 Tislelizumab monotherapy for patients with previously treated advanced hepatocellular carcinoma (HCC): RATIONALE-208 Chinese subpopulation
Authors: Z. Ren, Z. Li, T. Zhang, W. Fang, S. Hu, H. Pan, C. Yen, J. Hou, Y. Chen, G. Shao, C. Hsu, Y. Bai, Z. Meng, M. Hou, C. Xie, Y. Liu, J. Wu, B. Li, S. Chica-Duque, A. Cheng
Journal: Annals of Oncology (2022)
P-53 A phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in patients with HER2-high and HER2-low gastric or gastroesophageal junction (GEJ) adenocarcinoma
Authors: G. Ku, S. Piha-Paul, M. Gupta, D. Oh, Y. Kim, J. Lee, S. Rha, Y. Kang, M. Díez García, T. Fleitas Kanonnikoff, V. Arrazubi, K. Aviano, T. Demuth
Journal: Annals of Oncology (2022)
P-28 Real-world observational study of MVASI in metastatic colorectal cancer patients in Canada: Baseline patient characteristics
Authors: W. Cheung, S. Samimi, S. Kassam, B. Colwell, P. Meyer, G. Knight, K. Ma, M. Eberg, J. Mancini, M. Alemayehu, D. Martinez, M. Packalen, R. Wani, E. Ngan, Y. Du, N. Inam
Journal: Annals of Oncology (2022)
PD-13 Plasma RAS dynamics and efficacy of anti-EGFR rechallenge in patients with RAS/BRAF wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials
Authors: Y. Kagawa, D. Kotani, H. Bando, N. Takahashi, Y. Horita, A. Kanazawa, T. Kato, K. Ando, H. Satake, E. Shinozaki, Y. Sunakawa, A. Takashima, K. Yamazaki, S. Yuki, H. Nakajima, Y. Nakamura, M. Wakabayashi, H. Taniguchi, T. Ohta, T. Yoshino
Journal: Annals of Oncology (2022)
Human-centred mechanism design with Democratic AI
Authors: Raphael Koster, Jan Balaguer, Andrea Tacchetti, Ari Weinstein, Tina Zhu, Oliver Hauser, Duncan Williams, Lucy Campbell-Gillingham, Phoebe Thacker, Matthew Botvinick, Christopher Summerfield
Journal: Nature Human Behaviour (2022)

Abstract Building artificial intelligence (AI) that aligns with human values is an unsolved problem. Here we developed a human-in-the-loop research pipeline called Democratic AI, in which reinforcement learning is used to design a social mechanism that humans prefer by majority. A large group of humans played an online investment game that involved deciding whether to keep a monetary endowment or to share it with others for collective benefit. Shared revenue was returned to players under two different redistribution mechanisms, one designed by the AI and the other by humans. The AI discovered a mechanism that redressed initial wealth imbalance, sanctioned free riders and successfully won the majority vote. By optimizing for human preferences, Democratic AI offers a proof of concept for value-aligned policy innovation.